{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Pajares MJ"],"funding":["NCI NIH HHS"],"pagination":["1129-36"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4874209"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["30(10)"],"pubmed_abstract":["Purpose
Antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF) pathway have yielded more modest clinical benefit to patients with non-small-cell lung cancer (NSCLC) than initially expected. Clinical data suggest a distinct biologic role of the VEGF pathway in the different histologic subtypes of lung cancer. To clarify the influence of histologic differentiation in the prognostic relevance of VEGF-mediated signaling in NSCLC, we performed a concomitant analysis of the expression of three key elements of the VEGF pathway in the earliest stages of the following two principal histologic subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (ADC).Patients and methods
We evaluated tumor cell expression of VEGF, VEGF receptor (VEGFR) 1, and VEGFR2 u"],"journal":["Journal of clinical oncology : official journal of the American Society of Clinical Oncology"],"pubmed_title":["Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung."],"pmcid":["PMC4874209"],"funding_grant_id":["P50 CA070907","P30 CA016672"],"pubmed_authors":["Pajares MJ","Montuenga LM","Wistuba II","Zudaire I","Timsit JF","Ezponda T","Brambilla C","Larrayoz M","Behrens C","Brambilla E","Torre W","Pio R","Agorreta J","Vesin A","Lozano MD","Field JK"],"additional_accession":[]},"is_claimable":false,"name":"Expression of tumor-derived vascular endothelial growth factor and its receptors is associated with outcome in early squamous cell carcinoma of the lung.","description":"Purpose
Antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF) pathway have yielded more modest clinical benefit to patients with non-small-cell lung cancer (NSCLC) than initially expected. Clinical data suggest a distinct biologic role of the VEGF pathway in the different histologic subtypes of lung cancer. To clarify the influence of histologic differentiation in the prognostic relevance of VEGF-mediated signaling in NSCLC, we performed a concomitant analysis of the expression of three key elements of the VEGF pathway in the earliest stages of the following two principal histologic subtypes: squamous cell carcinoma (SCC) and adenocarcinoma (ADC).Patients and methods
We evaluated tumor cell expression of VEGF, VEGF receptor (VEGFR) 1, and VEGFR2 u","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 Apr","modification":"2026-06-04T15:34:02.835Z","creation":"2019-03-27T02:14:11Z"},"accession":"S-EPMC4874209","cross_references":{"pubmed":["22355056"],"doi":["10.1200/JCO.2011.37.4231","10.1200/jco.2011.37.4231"]}}